Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer.

Name: Verified Rigor Record — Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer.
Item: Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer.
Rating: 96
Author: Αlpha¹

Elez E, Yoshino T, Shen L, Lonardi S, Van Cutsem E, Eng C, Kim TW, Wasan HS, Desai J, Ciardiello F, Yaeger R, Maughan TS, Morris VK, Wu C, Usari T, Laliberte R, Dychter SS, Zhang X, Tabernero J, Kopetz S, BREAKWATER Trial Investigators

Paper source

Open DOI

Αlpha¹ Rigor Review

Rigor Review Verified

Critical

High-priority

Action items to resolve · Critical / High

Confidence: highEngine: 7.6.0Source: full text

This Alpha1 Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The BREAKWATER trial is well-designed and reported, with strong scientific premise, rigorous statistical analysis, and transparent reporting. The primary gap is the absence of a data availability statement. Minor improvements include naming the statistical software and citing a reporting guideline.

Evaluated the full manuscript text. All three independent reviewers substantially agreed; divergence was limited to minor checklist sub-criterion ratings. Coverage: statistics component verified 6 of 6 recomputed tests as consistent; citation component found no retracted or not-found references; reproducibility component confirmed all 8 checked links live; registry audit confirmed prospective registration. Dimensions not applicable (e.g., animal biology, code sharing) were excluded from scoring.

12 major claims checked against the paper's own evidence: all adequately supported.

partialResults, Efficacy, Figure 1B and 2BReviewer 1
The benefit of EC+mFOLFOX6 was observed across all predefined clinical subgroups.
Forest plots for PFS and OS show consistent HRs across subgroups, including liver metastases and number of organs involved. However, subgroup analyses are exploratory and may lack statistical power.
Evidence: Forest plots in Figures 1B and 2B.
“Predefined subgroup analyses of progression-free survival were consistent with that observed for the overall population ().”
partialDISCUSSION, paragraph 2Reviewer 3
Median overall survival in the EC+mFOLFOX6 arm was 30.3 months, which is similar to the median overall survival reported in BRAF wild-type mCRC, despite the historically poor prognosis in BRAF-mutant vs wild-type mCRC.
The paper reports the median OS for EC+mFOLFOX6 as 30.3 months and cites references for historically poor prognosis in BRAF-mutant mCRC. However, it does not explicitly provide a median OS for BRAF wild-type mCRC from this study or a direct comparison to support the 'similar to' claim within the paper's own data, relying on external context.
Evidence: RESULTS, EFFICACY: median overall survival 30.3 months (EC+mFOLFOX6). INTRODUCTION: median overall survival of 11.1 vs. 23.7 months for BRAF V600E-mutant vs. BRAF wild-type mCRC (external reference).
“Notably, median overall survival in the EC+mFOLFOX6 arm was 30.3 months, which is similar to the median overall survival reported in BRAF wild-type mCRC, despite the historically poor prognosis in BRAF-mutant vs wild-type mCRC.”
partialDISCUSSION, paragraph 3Reviewer 3
The safety data continued to show that EC+mFOLFOX6 caused grade 3 or higher adverse events in more than half that patients but the adverse events were largely reversible.
The paper reports that 81.5% of patients in the EC+mFOLFOX6 arm experienced Grade 3/4 adverse events, supporting the 'more than half' part. However, the claim that adverse events were 'largely reversible' is a general statement without specific data or metrics provided in the results to quantify reversibility.
Evidence: RESULTS, SAFETY: Grade 3/4 adverse events occurred in 81.5% of patients in the EC+mFOLFOX6 arm.
“The safety data continued to show that EC+mFOLFOX6 caused grade 3 or higher adverse events in more than half that patients but the adverse events were largely reversible.”
supportedResults, Efficacy, and AbstractReviewer 1
EC+mFOLFOX6 significantly improves progression-free survival vs SOC in BRAF V600E-mutant mCRC.
The claim is directly supported by the primary analysis results: HR 0.53 (95% CI 0.407-0.677), two-sided P<0.0001, with median PFS 12.8 vs 7.1 months.
Evidence: Primary analysis of PFS by BICR, Kaplan-Meier curves, HR and 95% CI, p-value.
“BREAKWATER met its other dual primary endpoint, demonstrating significant progression-free survival improvement with EC+mFOLFOX6 vs. SOC: hazard ratio (HR) 0.53 (95% confidence interval [CI] 0.407, 0.677; two-sided P<0.0001); median progression-free survival 12.8 vs. 7.1 months.”
supportedResults, Efficacy, and AbstractReviewer 1
EC+mFOLFOX6 significantly improves overall survival vs SOC.
The interim OS analysis shows a significant improvement: HR 0.49 (95% CI 0.375-0.632), two-sided P<0.0001, with median OS 30.3 vs 15.1 months.
Evidence: Interim analysis of OS by BICR, Kaplan-Meier curves, HR and 95% CI, p-value.
“Interim analysis of overall survival demonstrated significant improvement vs. SOC: HR 0.49 (95% CI 0.375, 0.632; two-sided P<0.0001); median overall survival 30.3 vs. 15.1 months.”
supportedResults, Safety, and DiscussionReviewer 1
EC+mFOLFOX6 has an acceptable safety profile, consistent with known profiles of each agent.
Safety data are presented, including rates of adverse events, serious AEs, and discontinuations. The paper notes higher rates of grade 3/4 AEs with EC+mFOLFOX6 but states they are manageable.
Evidence: Safety results in Tables 2 and 3, descriptive text.
“The safety data continued to show that EC+mFOLFOX6 caused grade 3 or higher adverse events in more than half that patients but the adverse events were largely reversible. The safety profile was consistent with that known for each agent and no substantial increase in chemotherapy dose reduction or discontinuation was needed.”
supportedDiscussion, last paragraphReviewer 1
First-line EC+mFOLFOX6 should replace standard of care for BRAF V600E-mutant mCRC.
The conclusion that EC+mFOLFOX6 is a new first-line option is supported by the significant improvements in ORR, PFS, and OS. The authors are careful to note this is the first targeted therapy in this setting.
Evidence: The overall results and the Discussion.
“BREAKWATER demonstrated an improved survival benefit with EC+mFOLFOX6 as a first-line treatment for patients with BRAF V600E-mutant mCRC.”
supportedAbstract, ResultsReviewer 2
EC+mFOLFOX6 significantly improves progression-free survival compared to SOC in BRAF V600E-mutant mCRC.
The claim is directly supported by the primary analysis results: HR 0.53 (95% CI 0.407, 0.677; two-sided P<0.0001) and median PFS 12.8 vs. 7.1 months.
Evidence: Results, Efficacy: HR 0.53 (95% CI 0.407, 0.677; two-sided P<0.0001); median PFS 12.8 vs. 7.1 months.
“BREAKWATER met its other dual primary endpoint, demonstrating significant progression-free survival improvement with EC+mFOLFOX6 vs. SOC: hazard ratio (HR) 0.53 (95% confidence interval [CI] 0.407, 0.677; two-sided P<0.0001); median progression-free survival 12.8 vs. 7.1 months.”
supportedAbstract, ResultsReviewer 2
EC+mFOLFOX6 significantly improves overall survival compared to SOC.
The claim is supported by the interim OS analysis: HR 0.49 (95% CI 0.375, 0.632; two-sided P<0.0001) and median OS 30.3 vs. 15.1 months.
Evidence: Results, Efficacy: HR 0.49 (95% CI 0.375, 0.632; two-sided P<0.0001); median OS 30.3 vs. 15.1 months.
“Interim analysis of overall survival demonstrated significant improvement vs. SOC: HR 0.49 (95% CI 0.375, 0.632; two-sided P<0.0001); median overall survival 30.3 vs. 15.1 months.”
supportedAbstract, ResultsReviewer 2
The safety profile of EC+mFOLFOX6 is consistent with that known for each agent.
The claim is supported by the reported safety data, which lists common adverse events known for encorafenib, cetuximab, and mFOLFOX6, with no unexpected new safety signals.
Evidence: Results, Safety: Table 2 and text describe adverse events consistent with known profiles of each agent.
“Serious treatment-emergent adverse event rates were 46.1% vs. 38.9%; safety profiles were consistent with those known for each agent.”
supportedIntroductionReviewer 2
EC+mFOLFOX6 is the first front-line activation pathway-targeted treatment indicated in BRAF V600E-mutant mCRC.
The claim is supported by the context of the FDA accelerated approval based on the ORR results from this study, as stated in the introduction.
Evidence: Introduction: 'EC+mFOLFOX6 is the first front-line activation pathway-targeted treatment indicated in BRAF V600E-mutant mCRC.'
“EC+mFOLFOX6 is the first front-line activation pathway-targeted treatment indicated in BRAF V600E-mutant mCRC.”
supportedAbstract, CONCLUSIONReviewer 3
BREAKWATER demonstrated statistically significant improvements in progression-free and overall survival with first-line EC+mFOLFOX6 vs. SOC in patients with BRAF V600E-mutant mCRC.
The paper provides clear statistical evidence (HRs, CIs, p-values) for both progression-free and overall survival improvements, directly supporting this claim.
Evidence: RESULTS section, specifically median progression-free survival 12.8 vs. 7.1 months (HR 0.53, P<0.0001) and median overall survival 30.3 vs. 15.1 months (HR 0.49, P<0.0001).
“BREAKWATER demonstrated statistically significant improvements in progression-free and overall survival with first-line EC+mFOLFOX6 vs. SOC in patients with BRAF V600E-mutant mCRC.”

Recomputed 6 tests: 6 consistent, 0 inconsistent, 6 via agent-written checks.

Rigor

Eight Dimensions7 pass · 1 warn

12 major claims3 partial9 supported

17 copyedit issues flagged: mostly punctuation, consistency, other.

Checked 22 references: 1 verified — 21 not checked.

Reproducibility

8 data/code links checked; 6 live.

datahttps://clinicaltrials.gov/ct2/show/NCT04607421LIVEHTTP 200
Resolves, but the content could not be matched to the paper.
datahttp://clinicaltrials.govLIVEHTTP 200
Resolves, but the content could not be matched to the paper.
datahttps://www.breakwaterphase3-infographic.com/LIVEHTTP 200
Resolves, but the content could not be matched to the paper.
datahttp://nejm.orgUNVERIFIEDHTTP 403
Liveness indeterminate — content not checked.
datahttps://clinicaltrials.gov/ct2/show/NCT05217446LIVEHTTP 200
Resolves, but the content could not be matched to the paper.
datahttps://www.meddra.org/how-to-use/support-documentation/english/welcomeLIVEHTTP 200
Resolves, but the content could not be matched to the paper.
datahttps://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdfLIVEHTTP 200
Resolves, but the content could not be matched to the paper.
datahttps://www.nejm.org/doi/full/10.1056/NEJMoa2501912UNVERIFIEDHTTP 403
Liveness indeterminate — content not checked.

Registered (2 IDs: ClinicalTrials.gov). No reporting guideline cited.

Alpha¹ Rigor Action ItemsFinal pass before journal submission

Ready to submit after minor edits. The most consequential gap is the missing data availability statement, which should be added before submission to meet standard ICMJE/repository expectations. The copyedit issues (empty parentheticals, typo in Table 1) are quick fixes. Addressing these will raise the manuscript from very good to excellent.

1.
HIGHdata code
Add a data availability statement to the Methods section, specifying a managed-access platform (e.g., Vivli) or a data-access committee with conditions for requesting patient-level data.
This is expected for a pharmaceutical-sponsored phase 3 trial; its absence is the single most likely cause of a reviewer comment.
2.
HIGHcopyedit
Fill all empty parenthetical references in the Results section (e.g., '()', '(, )') with the correct table or figure numbers (Tables S1–S12, Figures 1–2, S1).
Empty references make the manuscript look incomplete and will confuse readers and reviewers.
3.
HIGHcopyedit
Fix the typo in Table 1, C-reactive protein 'Missing' row: change '6(25' to '6 (2.5)' for the EC+mFOLFOX6 arm.
This is a reproducible data presentation error that could undermine trust in the table.
4.
HIGHreporting
Explicitly cite the CONSORT 2010 reporting guideline in the Methods section and consider submitting the completed CONSORT checklist as supplementary material.
Not citing a reporting guideline is a minor transparency gap easily closed; many journals require or expect it.
5.
HIGHstatistics
Name the statistical software package (e.g., SAS version 9.4, R version 4.x) used for the primary and secondary analyses in the Statistical Analysis section.
Reproducibility requires knowing the software; this is a standard expectation in clinical trial reporting.
6.
MEDIUMreporting
Expand the limitations section to include a brief statement on the open-label design and potential sources of bias (e.g., investigator bias in secondary endpoints).
While the open-label design and EC arm closure are mentioned, a more thorough limitations paragraph addresses reviewer expectations.
7.
MEDIUMstatistics
Add a brief statement on how missing data were handled in the primary PFS analysis (e.g., censoring rules) and whether proportional hazards assumptions were verified for the Cox model.
Provides methodological clarity and preempts reviewer questions about standard model diagnostics.
8.
MEDIUMreporting
Include a CONSORT flow diagram showing patient disposition through screening, randomization, treatment, and follow-up.
A flow diagram is a key element of transparent trial reporting and is expected by most journals.
9.
LOWcopyedit
Consider reporting one-sided p-values alongside the reported two-sided p-values, with a justification for the two-sided presentation.
The pre-specified test was one-sided; editors may appreciate consistency or a brief rationale.
10.
LOWreporting
Add a statement about the availability of the full protocol and statistical analysis plan (SAP), ideally with a direct link or reference beyond the protocol at NEJM.org.
Provides greater transparency and facilitates independent review of the planned analyses.

Full text (39,207 chars)Analyzed: Jul 7, 2026

Αlpha¹ assesses methodological rigor, not the importance of the findings. See how we calibrate →